XTalks

FEBRUARY 5, 2024

It is prescribed for the treatment of metastatic breast cancer in patients with HR-positive/HER2-negative status. Novartis attributed the growth to increased recognition of the drug’s life-extension benefit in metastatic breast cancer. million the drug made during the same time in 2022. For Kisqali, sales reached $1.5

FDA Approval 101

FDA Approval Drugs Sales Development 101

XTalks

FEBRUARY 5, 2024

It is prescribed for the treatment of metastatic breast cancer in patients with HR-positive/HER2-negative status. Novartis attributed the growth to increased recognition of the drug’s life-extension benefit in metastatic breast cancer. million the drug made during the same time in 2022. For Kisqali, sales reached $1.5

FDA Approval 52

FDA Approval Drugs Sales Development 52

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. US Orphan Drug designation was given to Saphnelo (anifrolumab), a treatment for idiopathic inflammatory myopathies. billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

MAY 4, 2021

On December 21, 2020, which falls in Pfizer’s international first-quarter 2021, Pfizer and Viatris completed the termination of a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan collaboration) and Pfizer transferred related operations that were part of the Mylan-Japan collaboration to Viatris.

Vaccination 40

Vaccination Vaccine Production Sales 40